Keyword: Merrimack Pharmaceuticals
Merrimack CEO becomes Yumanity chief; Lilly Bio-Medicines head leaves key launches behind; and 23andMe's drug leader exits for biotech board roles.
Last month, Richard Peters was the chief executive of struggling Merrimack; today, he’s the new CEO at Fierce 15 winner Yumanity.
Merrimack's CEO, CFO and president abandon ship; uBiome overhauls management amid FBI probe; and Gottlieb joins Pfizer’s board.
Two months after safety issues put an end to its clinical-stage pipeline, Merrimack's CEO, chief financial officer and president are bidding it adieu.
Merrimack is dumping another cancer therapy and swinging the ax across its already severely depleted workforce.
Jnana’s Joanne Kotz to be CEO; BioCardia brings on new clinical VP for phase 3; and Biomatics recruits biopharma veterans for $300M healthcare fund.
The major restructuring is intended to keep Merrimack operating and raking in milestones from Ipsen while it looks into strategic alternatives.
The setback, Merrimack Pharmaceuticals' second flop in four months, wiped 35% off the company’s stock and left its rebooted strategy in tatters.
Merrimack Pharmaceuticals has dropped MM-141 after the pancreatic cancer therapy failed to move the needle in a midphase trial.
Partner Therapeutics will build its portfolio by acquiring promising programs.